News/Media

Mycrodose Therapeutics Nominated for Company of the Year at Industry’s Top BioPharma Psychedelic Conference

by Patrick Eckstrom

Mycrodose Therapeutics has been nominated for the Company of the Year Award at the annual Wonderland-Miami Event taking place November 3-5, 20...

Read more

Kelai Pharmaceuticals & DoubleRainbow Biosciences Collaborate on Novel Natural Compound Therapeutics

by Patrick Eckstrom

Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioenginee...

Read more

Mycrodose Therapeutics Successfully Delivers Both Macro and Microdose Levels of Psilocin Using Core Drug Delivery Technologies

by Patrick Eckstrom

Mycrodose Therapeutics showed the ability to synthesize and stabilize psilocin in their laboratory for use in their IP-protected drug delivery sy...

Posted in advanced drug delivery, biotech, life science, pharmaceutical, psychedelic medicine

Read more

Mycrodose Therapeutics Announces First Clinical Candidate for Ketamine-Based Drug Delivery Device for Oral Mucositis

by Patrick Eckstrom

San Diego, California--(Newsfile Corp. - March 31, 2022) Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in...

Read more

Mycrodose Granted DEA/FDA Approval to Cultivate Psilocybin Mushrooms

by Patrick Eckstrom

DEA approval allows Mycrodose Therapeutics to become the first vertically-integrated US Pharmaceutical company utilizing psilocybin-based psychedel...

Read more

WATCH VIDEO - #1 Podcast by Empath Ventures - Mycrodose Therapeutics Overview: Team, Technology, Patents, Preclinical Pipeline, and 2022 Milestones / Strategy

by Patrick Eckstrom

Read more

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

by Patrick Eckstrom

Thu, February 10, 2022, 5:00 AM·6 min read The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica f...

Read more

Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program

by Patrick Eckstrom

VANCOUVER, BC, Dec. 16, 2021 /PRNewswire via COMTEX/ -- VANCOUVER, BC, Dec. 16, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE...

Read more

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes

by Patrick Eckstrom

The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week. VANCO...

Read more

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

by Patrick Eckstrom

Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders VANCOUVER, BC, Oct. 19, 2021 /PRNewswire/ - October 19,...

Read more

Mycrodose Therapeutics Expands Scientific Advisory Board with the Addition of Dr. Yavorsky and Dr. Jacques

by Patrick Eckstrom

San Diego, California--(December 14, 2021) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company developing advanced drug d...

Read more

Mycrodose Therapeutics Secures Supply and Distribution MOU With HAVN Life

by Patrick Eckstrom

The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week. VANCOU...

Read more